Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer

Hiroyuki Yasuda, Eunyoung Park, Cai Hong Yun, Natasha J. Sng, Antonio R. Lucena-Araujo, Wee Lee Yeo, Mark S. Huberman, David W. Cohen, Sohei Nakayama, Kota Ishioka, Norihiro Yamaguchi, Megan Hanna, Geoffrey R. Oxnard, Christopher S. Lathan, Teresa Moran, Lecia V. Sequist, Jamie E. Chaft, Gregory J. Riely, Maria E. Arcila, Ross A. SooMatthew Meyerson, Michael J. Eck, Susumu S. Kobayashi, Daniel B. Costa

Research output: Contribution to journalArticle

214 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19 deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC). However, EGFR exon 20 insertion mutations (∼10% of all EGFR mutations) are generally associated with insensitivity to available TKIs (gefitinib, erlotinib, and afatinib). The basis of this primary resistance is poorly understood. We studied a broad subset of exon 20 insertion mutations, comparing in vitro TKI sensitivity with responses to gefitinib and erlotinib in NSCLC patients, and found that most are resistant to EGFR TKIs. The crystal structure of a representative TKI-insensitive mutant (D770-N771insNPG) reveals an unaltered adenosine triphosphate-binding pocket, and the inserted residues form a wedge at the end of the C helix that promotes the active kinase conformation. Unlike EGFR-L858R, D770-N771insNPG activates EGFR without increasing its affinity for EGFR TKIs. Unexpectedly, we find that EGFR-A763-Y764insFQEA is highly sensitive to EGFR TKIs in vitro, and patients whose NSCLCs harbor this mutation respond to erlotinib. Analysis of the A763-Y764insFQEA mutant indicates that the inserted residues shift the register of the C helix in the N-terminal direction, altering the structure in the region that is also affected by the TKI-sensitive EGFR-L858R. Our studies reveal intricate differences between EGFR mutations, their biology, and their response to EGFR TKIs.

Original languageEnglish
Article number216ra177
JournalScience translational medicine
Volume5
Issue number216
DOIs
Publication statusPublished - 2013 Dec 18

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Yasuda, H., Park, E., Yun, C. H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W. L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., Yamaguchi, N., Hanna, M., Oxnard, G. R., Lathan, C. S., Moran, T., Sequist, L. V., Chaft, J. E., Riely, G. J., Arcila, M. E., ... Costa, D. B. (2013). Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Science translational medicine, 5(216), [216ra177]. https://doi.org/10.1126/scitranslmed.3007205